Phase 4 Completed N=112 Randomized Treatment

Chewed Versus Integral Pill of Ticagrelor

Percutaneous Coronary Intervention

Source: ClinicalTrials.gov NCT03708588 ↗

Enrolled (actual)

112

Serious AEs

9.6%

Results posted

Jan 2023

Primary outcomePrimary: Concentration of Pharmacodynamics — 142.5; 210 platelet reaction units

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug absorption and decreased platelet reactivity as compared to integral pill form 1 hour after drug administration.

Outcome Measures

Outcome	Result	p-value
PRIMARY Concentration of Pharmacodynamics	142.5; 210	—
SECONDARY Number of Participants With Major Adverse Cardiac and Cerebrovascular Event (MACCE)	4; 2	—

Eligibility Criteria

Inclusion Criteria

All patients presenting to the cardiac catheterization lab for percutaneous coronary intervention.

Exclusion Criteria

Age 89 years
Known coagulopathy, bleeding diathesis, or active bleeding
History of recent gastrointestinal or genitourinary bleed within 2 months
Known chronic therapy with clopidogrel, prasugrel, or ticagrelor
Major surgery within last 6 weeks
History of intracranial bleed or intracranial neoplasm
Suspected aortic dissection
Severe hemodynamic instability, cardiogenic shock
Life expectancy <1 year
Known severe liver or renal disease
Known HIV treatment
Any use of Glycoprotein inhibitors (GP IIb-IIIa) 48-hours before the procedure or any use during the procedure
Any use of Cangrelor during or after the procedure
Hemoglobin <10 g/dL, platelet (PLT) <100x10^9/L
Pregnancy
Known allergy to study medication

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03708588). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.